TARA — Protara Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1359931 ·
Last close
$2.32
Market Cap
$137.10M
52W High
$7.82
52W Low
$2.09
ADV30
905,942
Next earnings
2026-11-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -23,154,000 | -21,688,000 | 156,541,000 | 25,150,000 | 15,518,000 |
| Jun 2026 | 0 | — | -23,324,000 | -21,668,000 | 176,093,000 | 17,076,000 | 14,782,000 |
| Mar 2026 | 0 | — | -19,629,000 | -17,782,000 | 191,923,000 | 14,737,000 | 10,715,000 |
| Dec 2025 | 0 | — | -19,079,000 | -17,307,000 | 209,468,000 | 49,657,000 | 13,056,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-66,134,000
Investing CF
$-30,381,000
Financing CF
$82,095,000
CapEx
$-94,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.35
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-341,869,000
Inventory
—
Receivables
$1,277,000
ST Investments
$125,418,000
EBIT TTM
$-76,792,000
Pretax Income TTM
$-70,015,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -64,549,000 | -57,439,000 | 209,468,000 | 13,056,000 | 196,412,000 | -56,365,000 |
| Dec 2024 | 0 | -49,154,000 | -44,596,000 | 181,454,000 | 14,320,000 | 167,134,000 | -35,808,000 |
| Dec 2023 | 0 | -43,613,000 | -40,420,000 | 78,954,000 | 10,633,000 | 68,321,000 | -37,557,000 |
| Dec 2022 | 0 | -37,545,000 | -65,952,000 | 113,290,000 | 11,207,000 | 102,083,000 | -26,457,000 |
TTM Snapshot
Revenues TTM
$6,528,000
NetIncome TTM
$-70,015,000
OpCashFlow TTM
—
Assets (Latest)
$176,093,000
Forward EPS
$-1.69
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $2.34 · call volume: 50 · put volume: 8
Expected Move to 2027-02-19:
±$1.15
(49.15%) —
implied range
$1.19 –
$3.49
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HUMA | Humacyte, Inc. | $139.18M | $0.50 | — |
| STRO | SUTRO BIOPHARMA, INC. | $148.08M | $8.92 | — |
| IPHA | Innate Pharma SA | $148.56M | $1.33 | — |
| IVVD | Invivyd, Inc. | $151.09M | $0.51 | — |
| FATE | FATE THERAPEUTICS INC | $124.00M | $1.02 | — |
News headlines (Yahoo Finance, 1h cache)
Protara Therapeutics: Q3 Earnings Snapshot
2026-11-06 13:06 · Yahoo
Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update
2026-11-06 13:00 · Yahoo
Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
2026-10-15 12:00 · Yahoo
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 20:05 · Yahoo
What Makes Protara Therapeutics (TARA) a New Buy Stock
2026-07-21 16:00 · Yahoo
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
2026-05-15 11:00 · Yahoo
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
2026-04-27 20:05 · Yahoo
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
2026-05-20 12:00 · Yahoo
One Protara Therapeutics Insider Raised Their Stake In The Previous Year
2026-05-04 10:15 · Yahoo
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
2026-08-11 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.